Bodhi Tree Biotechnology Inc (BDTB) — Quarterly Report

AI-Powered SEC Filing Analysis

Latest Quarterly Report Filed: 2026-05-14

Key Insights

Company is severely cash-constrained with only $22,750 in cash as of March 31, 2026, down 79% from $109,404 six months prior, raising immediate liquidity concerns for ongoing operations.
Accumulated deficit has grown to $293,763 with net losses of $82,144 for the six-month period, while revenue remains minimal at $15,000, indicating the company is not generating meaningful business traction.
General and administrative expenses of $95,883 for six months significantly exceed the company's revenue, demonstrating an unsustainable burn rate with no clear path to profitability or operational viability.
The company is a non-accelerated filer, smaller reporting company, and emerging growth company trading OTC, suggesting limited resources, visibility, and market capitalization to support business development.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-13

Bodhi Tree Biotechnology Inc. reported a net loss of $52,948 for the quarter ended December 31, 2025, an improvement from the $64,777 loss in the same period of the prior year.
The company's cash balance declined to $47,366 as of December 31, 2025, down from $109,404 at the end of the prior quarter, indicating potential liquidity concerns.
Bodhi Tree Biotechnology did not generate any revenue during the quarter, a decline from the $5,000 in revenue reported in the same period of the prior year, raising questions about the company's commercial progress.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.